The Severity of COVID 19 in Diabetes and Non-diabetes Patients (COVID19)
Study on Characteristics and Prognosis of Diabetes and Non Diabetes Patients With COVID 19 Among Southern Indian Population
There were 83,85,440 confirmed cases of COVID-19 worldwide with a mortality rate of 5.4% according to the situation report of the World Health Organisation on June 19, 2020. In India there were 3,95,048 confirmed cases of COVID-19 with a mortality rate of 3.3%. In Tamil Nadu there were 54,449 confirmed cases of COVID-19 with a mortality rate of 1.2% according to the report of Ministry of Health and Family Welfare, Government of India on June 19, 2020.
COVID-19 infection is a double challenge for people with diabetes. India has a large number of persons with diabetes (more than 77 million). Recent studies have reported rising prevalence both in the urban and rural populations. The incidence of type 2 diabetes (T2D) also shows an increasing trend in the last few decades. Mortality seems to be threefold higher in people with diabetes when COVD-19 coexists when compared with mortality due to COVID-19 without comorbidities.
Yang et al noted that among 52 intensive care patients who had COVID 19 infection, 22% had diabetes among the non-survivors. In a study of 173 patients with severe disease, 16.2% had diabetes, and in another study of 140 hospitalized patients, 12% had diabetes. Li et al compared intensive care and non-intensive care patients who had COVID-19. They showed a twofold increase in the incidence of diabetes in intensive care patients.
In addition to diabetes; the other common co-morbidities present in COVID 19 patients were hypertension (20%), cardiovascular disease (16%), and lung disease (6%). In this context, patients with diabetes have been listed as people with higher severity for COVID-19 by several health authorities. However, precise data regarding patients with and without diabetes having COVID-19 infection are still lacking. Moreover, the relationship between diabetes and the severity of COVID-19 remains unknown. In this study, we intend to identify the disease severity and mortality in people with and without diabetes admitted for COVID-19 in southern India.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The following data from a person tested positive for COVID 19 and hospitalized will be collected. Patient's anthropometry (height in cms, weight in kgs and body mass index in kg/m2), blood pressure, symptoms of COVID-19 (fever, fatigue, cough, cephalalgia, dyspnoea, rhinitis, pharyngeal symptoms, ageusia, anosmia, digestive disorders), history of smoking, hypertension, dyslipidemia, microvascular (retinopathy, nephropathy and neuropathy), macrovascular (coronary artery disease, cerebrovascular disease and peripheral vascular disease) complications and other co morbid conditions will be recorded. Fasting blood glucose, HbA1c and any other relevant investigations if available and treatment for COVID-19 and other co morbid conditions will be recorded.
Details of patients developing new symptoms, shifted to ICU, intubated or died during the course of treatment will be recorded. Appearance of any complication during the stay at hospital will be recorded. The changes in the treatment pattern during the course of the disease will also be noted.
The registry will be fully anonymised and statistician will have no access to patients' personal identifiers. All "investigators" will have to register before entering data in the registry. Data about clinical observations for the individual patient will be entered by clinicians or by authorised research personnel of the care team in the web registry.
Patients' name, date of birth, date of death, residential postal code, hospital number will be fully anonymised at source. In no circumstances, patients' identifiable data be available to anyone outside their own care teams or authorised local administration/research personnel. Patient data will not at any stage will be in identifiable form by the registry managers. The data to be collected from the patients are mentioned in the visit chart.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ambady Ramachandran, M.D,PhD,DSc
- Numéro de téléphone: 044-22353730
- E-mail: research@ardiabetes.org
Lieux d'étude
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Inde, 600014
- Orthomed Hospital
-
Contact:
- Subair Khan, M.S
-
Chennai, Tamil Nadu, Inde, 600024
- Medway Hospital
-
Contact:
- Palaniappan T, M.D
-
Chennai, Tamil Nadu, Inde, 600035
- Venkateswara Hospital
-
Contact:
- Su Thillai Vallal, M.D
-
Chennai, Tamil Nadu, Inde, 600044
- Dr. Rela Institute & Medical Center
-
Contact:
- Sruti Chandrasekaran, M.D.,D.M
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- >18 yrs male or female
- COVID-19 positive
Exclusion Criteria:
- COVID 19 Negative
- New-onset Diabetes with covid-19 infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
COVID 19 positive patients without diabetes
|
|
COVID 19 positive patients with diabetes
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Severity of COVID 19 among people with and without diabetes
Délai: Up to 1 month
|
To identify the disease severity and outcome among people with and without diabetes hospitalized for COVID 19 virus infection
|
Up to 1 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of patients who were in ICU
Délai: Up to 1 month
|
Number of patients who were in ICU
|
Up to 1 month
|
|
Number of patients who had tracheal intubation
Délai: Up to 1 month
|
Number of patients who had tracheal intubation
|
Up to 1 month
|
|
Number of patients who had respiratory complication
Délai: Up to 1 month
|
Number of patients who had respiratory complication
|
Up to 1 month
|
|
Number of death
Délai: Up to 1 month
|
Number of death
|
Up to 1 month
|
|
Correlation of BMI with complications, tracheal intubation and mortality
Délai: Up to 1 month
|
Correlation of BMI with complications, tracheal intubation and mortality
|
Up to 1 month
|
|
Length of hospital stay
Délai: Up to 1 month
|
Length of hospital stay
|
Up to 1 month
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Ambady Ramachandran, M.D,PhD,DSc, President
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles du métabolisme du glucose
- Maladies métaboliques
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Pneumonie virale
- Pneumonie
- Maladies pulmonaires
- Maladies du système endocrinien
- COVID-19 [feminine]
- Diabète sucré
Autres numéros d'identification d'étude
- IDRFARH015
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Covid19
-
Anavasi DiagnosticsPas encore de recrutement
-
Ain Shams UniversityRecrutement
-
Israel Institute for Biological Research (IIBR)Complété
-
Colgate PalmoliveComplété
-
Christian von BuchwaldComplété
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActif, ne recrute pas
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichInscription sur invitation
-
Alexandria UniversityComplété